← All articles

Medical research does not have a funding problem. It has an efficiency problem.

Every year, the biomedical research system consumes hundreds of billions. Yet an estimated 85% of research investment is wasted. Not because science fails. Because incentives fail.

The waste is structural. It happens from start to finish.

Researchers often study the wrong questions. Topics that generate publications get attention, while real patient priorities are ignored. In knee osteoarthritis, around 80% of trials focus on drugs, while only 9% of patients consider drugs a priority. Patients care more about mobility, physiotherapy, surgery, and long-term quality of life.

Then comes poor design. Many studies are launched without properly reviewing existing evidence. That means duplicated trials, avoidable risks, and money spent answering questions already answered.

Then comes silence. More than half of studies are never fully published. Negative or inconvenient findings disappear.

Then comes unusable reporting. Methods are vague, outcomes are selectively reported, and replication becomes impossible.

The result is not just wasted capital. It is delayed progress, weaker decisions, and patients waiting longer for solutions.

And then there is the reproducibility crisis. If results cannot be replicated, they cannot be trusted. Several industry reviews have shown a large share of influential academic findings fail this basic test.

This is not a productivity issue. It is an incentive issue.

When institutions reward volume over value, researchers optimize for papers instead of progress. More output. Less impact.

What needs to change is obvious.

Fund research that reflects patient and clinical priorities. Require evidence reviews before approving new studies. Publish all results, not only positive ones. Reward rigor, transparency, and relevance.

Science does not need more noise. It needs better incentives.